Matthew K. Fust - Jul 13, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jul 13, 2022
Transactions value $
-$111,190
Form type
4
Date filed
7/15/2022, 04:30 PM
Previous filing
Jun 28, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $8.27K +5.7K +45.47% $1.45* 18.2K Jul 13, 2022 Direct F1
transaction CRNX Common Stock Sale -$119K -5.7K -31.26% $20.96 12.5K Jul 13, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -5.7K -100% $0.00* 0 Jul 13, 2022 Common stock 5.7K $1.45 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017.